The HealthTech Signal
Chai Discovery triples its valuation as pharma buys into AI-designed molecules
Chai Discovery triples its valuation as pharma buys into AI-designed molecules
Dr. Dereck Mush, MD, MBA
PhoreMost
Identifies novel druggable targets using high-throughput phenotypic screening platforms.
What they do
The company deploys its proprietary SITESEEKER technology to probe human disease biology and identify novel targets. Biopharmaceutical companies license this data to jumpstart pipeline development.
The record
- Vertical
- Biotech & Pharma
- Sub-segment
- Drug target discovery
- Product type
- Platform software
- Stage
- Series B
- Headquarters
- Cambridge, United Kingdom
- Region
- Europe
- Founded
- 2014
- Total funding
- $46M raised
Notable investors: BGF, Parkwalk Advisors, Amadeus Capital Partners, Astellas Venture Management.
Also in Biotech & Pharma
Related on The Signal
Dr. Dereck Mush, MD, MBA
AI is moving upstream, from molecule design into disease target identification itself
Dr. Dereck Mush, MD, MBA
Is AI Drug Discovery Actually Working? What the 2026 Clinical Trial Data Shows
Dr. Dereck Mush, MD, MBA
Transporter-Independent Pharmacology and the Orphan PRV Playbook
Dr. Dereck Mush, MD, MBA